Turning Science Into Products™

SynDevRx®, Inc. has developed a technology that increases the activity and safety of small molecule drugs using a proprietary conjugation technique.

Our technology increases a drug's therapeutic index by concentrating activity at the disease site.  It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile.

Our lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.  SDX-7320 has shown compelling activity and safety with a surprisingly large therapeutic index (>20) in pre-clinical animal experiments.   The technology keeps the active drug inert while in general circulation thereby greatly reducing toxicities associated with other drug conjugates that undergo non-specific hydrolytic degradation as well as all small molecule drugs that have general bio-distribution.

Our technology is available for partnering.